Slides on Key Decisions in HIV Care: Switching to Long-acting ART

See key clinical trial data and practical insights such as how to initiate a patient on long-acting therapy, recommended dosing regimens, and factors that may increase the risk of treatment failure.
Daniel R. Kuritzkes, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 529 KB
Released: June 4, 2021

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Slides from Dr Milena Murray and Clinical Care Options (CCO): Data suggests patient factors that may inform candidacy for LA CAB + RPV as a treatment option

person default Milena Murray, PharmD, MSc, BCIDP, AAHIVP Released: December 1, 2021

Clinical Care Options (CCO) expert analysis of new data from EACS 2021, provided by expert HIV faculty

person default Tristan J. Barber, MA, MD, FRCP Released: November 30, 2021

One patient’s journey from HIV diagnosis to undetectable while trying to lose weight, from Clinical Care Options (CCO)

person default Anonymous Patient Released: November 29, 2021

Perspective on ART modification to reduce CVD risk in PWH, from Dr Jens D. Lundgren and Clinical Care Options (CCO)

Jens D. Lundgren, MD, DMSc Released: November 29, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue